A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT07108816 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07108816
- Sponsor
- Henan Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-15
- Primary completion
- 2026-12-30
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.